Linear heteroaryl diamide ire1/xbp1s activators
AssigneeProtego Biopharma, Inc.
InventorsRichard F. LABAUDINIERE, Bradley Dean TAIT, Huang QIU, Hank Michael James PETRASSI, Bo QIN
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds that activate IREI/XBPIs, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject having a disease or disorder that may be ameliorated by increasing IREl/XBPls activity.
Claims130
A compound of Formula I:
- or a pharmaceutically acceptable derivative thereof, wherein:
- m, n, p and s are each independently an integer from 0-4;
- R1 is cycloalkyl or heterocycloalkyl;
- R2 is aryl or heteroaryl;
- X1 and X2 are each independently a bond, O, CONR15, SO2NR15 or NR15;
- X3 and X4 are each independently CR16 or N;
- X5 is CR17 or N;
- R3, R4 and R15 are each independently H, alkyl, aryl or aralkyl;
- R7 and R8 are each independently H, halo, alkyl, aryl or aralkyl, or together form spirocycloalkyl;
- R11 and R12 are each independently H, halo, alkyl, aryl or aralkyl, or together form spirocycloalkyl;
- and
- R5, R6, R9, R10, R13, R14, R16 and R17 are each independently H, halo, alkyl, aryl or aralkyl.
A compound of Formula II:
- or a pharmaceutically acceptable derivative thereof, wherein:
- a and b are each independently 2 or 3;
- R21 is heteroaryl, cycloalkyl or heterocycloalkyl;
- R22 is aryl or heteroaryl;
- X21 is a bond, O, CONR30, SO2NR30 or NR30;
- X22 is O, CONR31, SO2NR31 or NR31;
- and
- R23 and R24 are each independently H, alkyl, aryl, aralkyl, or together form spirocycloalkyl;
- R28 and R29 are each independently H, alkyl, aryl, aralkyl, or together form spirocycloalkyl;
- R25, R26, R27, R30 and R31 are each independently H, alkyl or aralkyl;
- with the proviso that R21 is not optionally substituted 2-pyridyl.
A compound that has Formula III:
- or a pharmaceutically acceptable derivative thereof, where R40 is aryl or heteroaryl.
A compound of Formula IV:
- or a pharmaceutically acceptable derivative thereof, wherein R41 is phenyl, 2-fluorophenyl or 2,6-difluorophenyl;
- and R42 is ethyl or trifluoromethyl;
- with the proviso that the compound is not N-(1-(2-(methyl-(2-(4-(trifluoromethyl)phenoxy)ethyl)amino)-2-oxoethyl)-1H-pyrazol-4-yl)-3-phenoxypropanamide.
A compound of Formula V:
- or a pharmaceutically acceptable derivative thereof, wherein R43 is alkoxy or halo;
- and R44 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl;
- with the proviso that the compound is not N-(1-(2-(methyl-(2-(p-tolyloxy)ethyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)-3-(2-fluorophenoxy)propanamide.
A compound of Formula VI:
- or a pharmaceutically acceptable derivative thereof, wherein R45 and R46 are each independently aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
A compound of Formula VII:
- or a pharmaceutically acceptable derivative thereof, wherein R21 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl;
- R22 is aryl or heteroaryl;
- R23, R28 and R29 are each independently H or alkyl with the proviso that at least one of R23, R28 and R29 is alkyl;
- and with the proviso that the compound is not N-(1-(2-(methyl-(2-(p-tolyloxy)ethyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)-3-(4-fluorophenoxy)-2-methylpropanamide.
A compound selected from Compounds 1-295.
Dependencies are inferred from the claim text.